Close
ACHEMA MIDDLE EAST 2026
5th LNP Formulation & Process Development Summit

Clinical Trials

Allergan Announces Positive Pivotal Trial Results for Oculeve Intranasal Tear Neurostimulator

Clinical Trials
Allergan plc announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met their primary and secondary efficacy endpoints....

Merck Receives Breakthrough Therapy Designation from U.S. FDA for KEYTRUDA in Classical Hodgkin Lymphoma (cHL)

Americas
Merck, known as MSD outside the United States and Canada, announced that the U.S. FDA has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the...

Advancing Patient Recruitment & Engagement in Clinical Trials

Clinical Trials
This whitepaper highlights some of the most advanced companies in their innovative approaches to trial recruitment. Witness first-hand 5 case study examples of how...

CABBVIE ANNOUNCES NEW ENGLAND JOURNAL OF MEDICINE ONLINE PUBLICATION OF VENETOCLAX PHASE 1 DATA IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Clinical Trials
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal of Medicine (NEJM) showing...

IBRUTINIB (IMBRUVICA®) COMBINATION DATA SHOW PROMISE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Clinical Trials
AbbVie , a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA®) plus carfilzomib...

IMBRUVICA® (IBRUTINIB) PHASE 3 RAY DATA SHOW SIGNIFICANT REDUCTIONS IN DISEASE PROGRESSION VERSUS TEMSIROLIMUS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS

Clinical Trials
- IMBRUVICA ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN KEY ENDPOINTS INCLUDING REDUCTION OF THE RISK OF DISEASE PROGRESSION OR DEATH VERSUS TEMSIROLIMUS CHEMOTHERAPY - PHASE...

Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA®

Americas
Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma   Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK),...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

Whitepapers 0
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

Whitepapers 0
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Whitepapers 0
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

About us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

Resources

Advertise

Subscribe

Copyright © Value Media Group 2026. All rights reserved.